Ningzhi Zhang

Dr. Ningzhi Zhang

Renmin Hospital of Wuhan University, Wuhan, Hubei, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2024 in Biomolecules
Verified
Journal Article
Open access
PDF file
YLYuchen Liu
Yuchen Liu
XZXin Zong
Xin Zong
CWCao Wenye
Cao Wenye
WZWenxi Zhang
Wenxi Zhang
NZNingzhi Zhang
Ningzhi Zhang
NYNing Yang
Ning Yang
Retinitis pigmentosa (RP) poses a significant threat to eye health worldwide, with prevalence rates of 1 in 5000 worldwide. This genetically diverse retinopathy is characterized by the loss of photoreceptor cells and atrophy of the retinal pigment epithelium. Despite the involvement of more than 3000 mutations across approximately 90 genes in its onset, finding an effective treatment has been challenging for a considerable time. However, advancements in scientific research, especially in gene therapy, are significantly expanding treatment options for this most prevalent inherited eye disease, with the discovery of new compounds, gene-editing techniques, and gene loci offering hope for more effective treatments. Gene therapy, a promising technology, utilizes viral or non-viral vectors to correct genetic defects by either replacing or silencing disease-causing genes, potentially leading to complete recovery. In this review, we primarily focus on the latest applications of gene editing research in RP. We delve into the most prevalent genes associated with RP and discuss advancements in genome-editing strategies currently employed to correct various disease-causing mutations.

29 January 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
XHXuejun He
Xuejun He
CWCao Wenye
Cao Wenye
ZWZhiyi Wang
Zhiyi Wang
NZNingzhi Zhang
Ningzhi Zhang
KXKexin Xu
Kexin Xu
NYNing Yang
Ning Yang
Submacular hemorrhage (SMH) is the accumulation of blood in the macular area that can severely damage the macular structure and visual function. Recently, the intraocular administration of tissue plasminogen activator (TPA) with anti-vascular endothelial growth factor (anti-VEGF) drugs was reported to have a positive effect on SMH. This meta-analysis aimed to explore the efficacy and safety of the drug combination. We systematically searched the Web of Science, MEDLINE, EMBASE, and Cochrane Library databases and screened relevant full-length literature reports. The quality of the reports was assessed by two independent reviewers. The best-corrected visual acuity (BCVA) and foveal thickness (FT) were considered the main indicators of efficacy. RevMan 5.4 software was used for this meta-analysis. Twelve studies were analyzed, and the results showed that BCVA at 1 month (p < 0.001), 3 months (p < 0.001), 6 months (p < 0.001), and the last follow-up (p < 0.001) was improved relative to the preoperative value. The postoperative FT was lower than the preoperative FT (p < 0.001). No significant difference in efficacy was observed between subretinal and intravitreal TPA injections (p = 0.37). TPA with anti-VEGF drugs is safe for SMH treatment and can significantly improve BCVA and reduce FT.

28 February 2022 in Cellular and Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
NZNingzhi Zhang
Ningzhi Zhang
CWCao Wenye
Cao Wenye
XHXuejun He
Xuejun He
YXYiqiao Xing
Yiqiao Xing
NYNing Yang
Ning Yang

1 November 2023 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
DCDuan Chen
Duan Chen
SMSen Miao
Sen Miao
XCXuemei Chen
Xuemei Chen
ZWZhiyi Wang
Zhiyi Wang
PLPei Lin
Pei Lin
NYNing Yang
Ning Yang

Verified
Journal Article
Open access
PDF file
XHXuejun He
Xuejun He
NZNingzhi Zhang
Ningzhi Zhang
CWCao Wenye
Cao Wenye
YXYiqiao Xing
Yiqiao Xing
NYNing Yang
Ning Yang
Ocular diseases affect multiple eye parts and can be caused by pathogenic infections, complications of systemic diseases, genetics, environment, and old age. Understanding the etiology and pathogenesis of eye diseases and improving their diagnosis and treatment are critical for preventing any adverse consequences of these diseases. Recently, the advancement of high-throughput sequencing (HTS) technology has paved wide prospects for identifying the pathogenesis, signaling pathways, and biomarkers involved in eye diseases. Due to the advantages of HTS in nucleic acid sequence recognition, HTS has not only identified several normal ocular surface microorganisms but has also discovered many pathogenic bacteria, fungi, parasites, and viruses associated with eye diseases, including rare pathogens that were previously difficult to identify. At present, HTS can directly sequence RNA, which will promote research on the occurrence, development, and underlying mechanism of eye diseases. Although HTS has certain limitations, including low effectiveness, contamination, and high cost, it is still superior to traditional diagnostic methods for its efficient and comprehensive diagnosis of ocular diseases. This review summarizes the progress of the application of HTS in ocular diseases, intending to explore the pathogenesis of eye diseases and improve their diagnosis.

19 March 2024 in Experimental Eye Research
Verified
Journal Article
Closed access
PLPei Lin
Pei Lin
CWCao Wenye
Cao Wenye
XCXuemei Chen
Xuemei Chen
NZNingzhi Zhang
Ningzhi Zhang
YXYiqiao Xing
Yiqiao Xing
NYNing Yang
Ning Yang